Comparative Effects of Serial Allogeneic and Autologous Platelet Lysate Administration in the Treatment of Equine Joint Diseases

• Grant number: 25/17062-6
• Support Opportunities: Scholarships in Brazil - Master
• Start date: September 01, 2025
• End date: July 31, 2026
• Field of knowledge: Agronomical Sciences - Veterinary Medicine - Animal Clinics and Surgery
• Principal Investigator: Raquel Yvonne Arantes Baccarin
• Grantee: Beatriz Constante Souza
• Host Institution: Faculdade de Medicina Veterinária e Zootecnia (FMVZ). Universidade de São Paulo (USP). São Paulo , SP, Brazil
• Associated research grant: 24/20820-7 - EFFICACY AND EFFECTIVENESS OF ALLOGENIC PLATELET LYSATE ON EQUINE JOINT TISSUE: IN VITRO, LABORATORY AND CLINICAL ASPECTS., AP.R

Abstract

Currently, the use of hemocomponent-based regenerative therapies for the treatment of joint diseases has been increasing, with platelet-rich plasma (PRP) commonly employed due to its high concentration of growth factors. However, given the challenges associated with the use of PRP, platelet lysate (PL) has attracted interest in both Human and Veterinary Medicine, as it offers similar therapeutic potential and advantages in terms of storage, availability, clinical application, and a lower likelihood of triggering a transient inflammatory process. In Human Medicine, studies using PL have shown promising results for a wide range of applications. Nevertheless, the autologous nature inherent to hemocomponent-based therapies may influence the concentration of growth factors and the quality of outcomes, as donor-related factors can directly impact the results. In this context, producing a pool of lysates from healthy donors may yield PL with greater therapeutic potential and reduced individual variability. Therefore, the present study aims to compare the results obtained from the use of autologous PL with those of allogeneic PL in the treatment of horses with joint diseases, as a way to provide a more efficient alternative in terms of logistics and outcomes, as well as to encourage further research into the potential of allogeneic PL for treatment in other areas of both Human and Veterinary Medicine. (AU)